On December 30, Sarah Fredriksson, CEO sold 522,880 shares in Genovis to NightGlow AB where her holdings amounts to 34%. The other shareholders of NightGlow AB are Fredrik Olsson, COO and Susanne Nykvist, IR / PR manager, all insiders in Genovis.
Find out more, contact: Sarah Fredriksson, CEO, Genovis AB Tel: +46 46 10 12 35 sarah.fredriksson@genovis.com
Genovis is a biotech company on the leading edge of nanotechnology and nanoparticles. The company’s patented nano-induced magnetic transfer (NIMT®) technology was developed to facilitate effective preclinical research for the life science industry. Genovis shares are listed on Nasdaq OMX First North and Thenberg & Kinde Fondkommission is our certified adviser.
